GlassScriptPhysician profile
Safiullah MD Shareef
NPI 1124317243
$10,918.61
in general payments reported to CMS, 2019-2025
53 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 76% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2020: $1,100 · 2021: $1,446 · 2022: $1,454 · 2023: $1,861 · 2024: $2,156 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,647.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,148.35 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Corium, LLC | $1,089.26 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $1,026.85 | 2019-2024 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $699.25 | 2019-2025 | |
| Neurelis, INC. | $523.03 | 2020-2025 | Valtoco |
| Tris Pharma INC | $476.55 | 2019-2025 | Dyanavel Xr, Quillivant |
| Acadia Pharmaceuticals INC | $446.94 | 2023-2025 | Daybue |
| Supernus Pharmaceuticals, INC. | $433.71 | 2021-2025 | Qelbree, Qelbree |
| Eisai INC. | $429.76 | 2019-2023 | |
| Immedica Pharma US, INC. | $411.70 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $370.13 | 2019-2022 | |
| Greenwich Biosciences, INC. | $270.23 | 2019-2021 | |
| Neos Therapeutics, LP | $263.61 | 2019-2023 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Sk Life Science, INC. | $252.01 | 2020-2025 | |
| Livanova USA, INC. | $241.14 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Safiullah Shareef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.